Display options
Cite
Tati S, Fisk JC, Abdullah J, et al. Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis. Neoplasia. 2017;19(9):716-733doi: 10.1016/j.neo.2017.07.001.
Tati, S., Fisk, J. C., Abdullah, J., Karacosta, L., Chrisikos, T., Philbin, P., Morey, S., Ghazal, D., Zazala, F., Jessee, J., Quataert, S., Koury, S., Moreno, D., Eng, J. Y., Glinsky, V. V., Glinskii, O. V., Sesay, M., Gebhard, A. W., Birthare, K., Olson, J. R., & Rittenhouse-Olson, K. (2017). Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis. Neoplasia (New York, N.Y.), 19(9), 716-733. https://doi.org/10.1016/j.neo.2017.07.001
Tati, Swetha, et al. "Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis." Neoplasia (New York, N.Y.) vol. 19,9 (2017): 716-733. doi: https://doi.org/10.1016/j.neo.2017.07.001
Tati S, Fisk JC, Abdullah J, Karacosta L, Chrisikos T, Philbin P, Morey S, Ghazal D, Zazala F, Jessee J, Quataert S, Koury S, Moreno D, Eng JY, Glinsky VV, Glinskii OV, Sesay M, Gebhard AW, Birthare K, Olson JR, Rittenhouse-Olson K. Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis. Neoplasia. 2017 Sep;19(9):716-733. doi: 10.1016/j.neo.2017.07.001. Epub 2017 Aug 19. PMID: 28830009; PMCID: PMC5565633.
Copy Download .nbib Format: NLM
Share it on

Neoplasia. 2017 Sep;19(9):716-733. doi: 10.1016/j.neo.2017.07.001. Epub 2017 Aug 19.

Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis.

Neoplasia (New York, N.Y.)

Swetha Tati, John C Fisk, Julia Abdullah, Loukia Karacosta, Taylor Chrisikos, Padraic Philbin, Susan Morey, Diala Ghazal, Fatma Zazala, Joseph Jessee, Sally Quataert, Stephen Koury, David Moreno, Jing Ying Eng, Vladislav V Glinsky, Olga V Glinskii, Muctarr Sesay, Anthony W Gebhard, Karamveer Birthare, James R Olson, Kate Rittenhouse-Olson

Affiliations

  1. For-Robin, Inc., Buffalo, NY. Electronic address: [email protected].
  2. For-Robin, Inc., Buffalo, NY. Electronic address: [email protected].
  3. Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, Buffalo, NY; For-Robin, Inc., Buffalo, NY; Department of Microbiology and Immunology, University at Buffalo, Buffalo, NY. Electronic address: [email protected].
  4. For-Robin, Inc., Buffalo, NY. Electronic address: [email protected].
  5. Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, Buffalo, NY; For-Robin, Inc., Buffalo, NY. Electronic address: [email protected].
  6. Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, Buffalo, NY. Electronic address: [email protected].
  7. Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, Buffalo, NY. Electronic address: [email protected].
  8. For-Robin, Inc., Buffalo, NY. Electronic address: [email protected].
  9. For-Robin, Inc., Buffalo, NY. Electronic address: [email protected].
  10. For-Robin, Inc., Buffalo, NY. Electronic address: [email protected].
  11. For-Robin, Inc., Buffalo, NY. Electronic address: [email protected].
  12. Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, Buffalo, NY. Electronic address: [email protected].
  13. Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, Buffalo, NY. Electronic address: [email protected].
  14. Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, Buffalo, NY. Electronic address: [email protected].
  15. Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, MO; Department of Pathology and Anatomical Sciences, University of Missouri, Columbia, MO. Electronic address: [email protected].
  16. Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, MO; Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO. Electronic address: [email protected].
  17. Goodwin Biotechnology, Inc., Plantation, FL. Electronic address: [email protected].
  18. Goodwin Biotechnology, Inc., Plantation, FL. Electronic address: [email protected].
  19. For-Robin, Inc., Buffalo, NY; Department of Pharmacology and Toxicology, University at Buffalo, Buffalo, NY. Electronic address: [email protected].
  20. Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, Buffalo, NY; For-Robin, Inc., Buffalo, NY. Electronic address: [email protected].

PMID: 28830009 PMCID: PMC5565633 DOI: 10.1016/j.neo.2017.07.001

Abstract

JAA-F11 is a highly specific mouse monoclonal to the Thomsen-Friedenreich Antigen (TF-Ag) which is an alpha-O-linked disaccharide antigen on the surface of ~80% of human carcinomas, including breast, lung, colon, bladder, ovarian, and prostate cancers, and is cryptic on normal cells. JAA-F11 has potential, when humanized, for cancer immunotherapy for multiple cancer types. Humanization of JAA-F11, was performed utilizing complementarity determining regions grafting on a homology framework. The objective herein is to test the specificity, affinity and biology efficacy of the humanized JAA-F11 (hJAA-F11). Using a 609 target glycan array, 2 hJAA-F11 constructs were shown to have excellent chemical specificity, binding only to TF-Ag alpha-linked structures and not to TF-Ag beta-linked structures. The relative affinity of these hJAA-F11 constructs for TF-Ag was improved over the mouse antibody, while T20 scoring predicted low clinical immunogenicity. The hJAA-F11 constructs produced antibody-dependent cellular cytotoxicity in breast and lung tumor lines shown to express TF-Ag by flow cytometry. Internalization of hJAA-F11 into cancer cells was also shown using a surface binding ELISA and confirmed by immunofluorescence microscopy. Both the naked hJAA-F11 and a maytansine-conjugated antibody (hJAA-F11-DM1) suppressed in vivo tumor progression in a human breast cancer xenograft model in SCID mice. Together, our results support the conclusion that the humanized antibody to the TF-Ag has potential as an adjunct therapy, either directly or as part of an antibody drug conjugate, to treat breast cancer, including triple negative breast cancer which currently has no targeted therapy, as well as lung cancer.

Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

References

  1. Curr Protoc Immunol. 2002 May;Chapter 2:Unit 2.12 - PubMed
  2. Int J Exp Pathol. 2011 Apr;92 (2):97-105 - PubMed
  3. Eur J Biochem. 1988 Nov 1;177(2):443-60 - PubMed
  4. Hybridoma. 1998 Apr;17(2):165-73 - PubMed
  5. Cancer. 1995 Nov 15;76(10):1700-8 - PubMed
  6. Oncol Rep. 1999 Mar-Apr;6(2):341-4 - PubMed
  7. Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17033-8 - PubMed
  8. Curr Opin Immunol. 2008 Aug;20(4):460-70 - PubMed
  9. Front Biosci (Schol Ed). 2012 Jan 01;4:840-63 - PubMed
  10. Acta Oncol. 2007;46(3):316-23 - PubMed
  11. Cancer Res. 2003 Jul 1;63(13):3805-11 - PubMed
  12. Hum Pathol. 1996 Dec;27(12):1341-7 - PubMed
  13. Appl Radiat Isot. 2008 Mar;66(3):278-87 - PubMed
  14. Cancer. 1996 May 1;77(9):1768-73 - PubMed
  15. Breast Cancer Res. 2010;12(3):204 - PubMed
  16. Breast Cancer Res. 2014 Mar 05;16(2):209 - PubMed
  17. Methods. 2005 May;36(1):3-10 - PubMed
  18. Am J Clin Pathol. 1990 Mar;93(3):315-21 - PubMed
  19. Exp Oncol. 2007 Mar;29(1):61-6 - PubMed
  20. Cancer Res. 1985 Mar;45(3):1187-97 - PubMed
  21. Nature. 1989 Dec 21-28;342(6252):877-83 - PubMed
  22. Urol Res. 1985;13(2):47-50 - PubMed
  23. Int J Cancer. 2008 Jul 1;123(1):89-99 - PubMed
  24. J Biol Chem. 1988 Jan 25;263(3):1157-65 - PubMed
  25. J Natl Cancer Inst. 1973 Nov;51(5):1417-23 - PubMed
  26. Cancer Res. 1989 Jan 1;49(1):32-7 - PubMed
  27. Mol Cancer. 2010 Jun 18;9:154 - PubMed
  28. Glycoconj J. 2007 Nov;24(8):411-20 - PubMed
  29. Methods Mol Biol. 2009;525:445-67, xiv - PubMed
  30. Cancer Res. 2000 May 15;60(10):2584-8 - PubMed
  31. PLoS One. 2013;8(1):e54874 - PubMed
  32. Am J Hematol. 1996 May;52(1):29-38 - PubMed
  33. BMC Biotechnol. 2013 Jul 05;13:55 - PubMed
  34. MAbs. 2014 Jan-Feb;6(1):34-45 - PubMed
  35. J Physiol. 2004 Jan 1;554(Pt 1):89-99 - PubMed
  36. BMC Cancer. 2010 Apr 30;10:177 - PubMed
  37. Eur J Nucl Med. 1985;10 (1-2):68-74 - PubMed
  38. Cancer Res. 2001 Jun 15;61(12):4851-7 - PubMed
  39. Int J Oncol. 2003 Dec;23(6):1585-92 - PubMed
  40. Cancer Res. 1985 Feb;45(2):879-85 - PubMed
  41. J Biol Chem. 1987 Apr 5;262(10):4733-9 - PubMed
  42. Neoplasia. 2005 May;7(5):522-7 - PubMed
  43. Oncotarget. 2014 Mar 15;5(5):1382-9 - PubMed
  44. Cancer Res. 1985 Jun;45(6):2913-23 - PubMed
  45. Future Oncol. 2014 Feb;10(3):385-99 - PubMed
  46. Urol Int. 1987;42(2):120-3 - PubMed
  47. Exp Oncol. 2005 Jun;27(2):136-40 - PubMed
  48. Curr Opin Pharmacol. 2005 Oct;5(5):543-9 - PubMed
  49. Oncoimmunology. 2012 Jul 1;1(4):477-486 - PubMed
  50. Cancer. 1980 Jun 15;45(12):2949-54 - PubMed
  51. J Biol Chem. 2007 Jan 5;282(1):773-81 - PubMed
  52. Science. 1984 Jun 15;224(4654):1198-206 - PubMed
  53. Eur J Nucl Med. 1997 Apr;24(4):381-9 - PubMed
  54. Tumour Biol. 1988;9(4):190-4 - PubMed
  55. Neoplasia. 2006 Nov;8(11):939-48 - PubMed

Publication Types

Grant support